整合方法揭示芎芷通络方抗缺血性卒中的作用
本研究结合网络节点相似性算法、UPLC-Q-TOF/MS 植物化学谱分析、网络药理学、分子对接、多中心随机对照试验及 MCAO 大鼠模型,探讨芎芷通络方(XZTLF)治疗缺血性卒中的机制。XZTLF 含 173 种生物活性成分,筛选出 8 个核心靶点并在患者中验证;大鼠实验显示 XZTLF 可减小脑梗死体积、改善神经功能,机制涉及抗神经炎症、抗氧化及抑制 PI3K/AKT 通路。
要点
- XZTLF 含 173 种生物活性成分,网络药理学筛选出 8 个缺血性卒中核心靶点。
- MCAO 大鼠中 XZTLF 灌胃可减小脑梗死体积并改善神经功能。
- 机制涉及下调 IL-6、TNF-α、NF-κB、调节 MDA/SOD/CAT 及抑制 PI3K/AKT。
核心结论
- 基于临床与临床前整合证据,XZTLF 可能通过多模式调控神经炎症级联、氧化还原稳态及自噬通路发挥抗缺血性卒中作用。
研究设计与样本
- 研究整合网络节点相似性算法、UPLC-Q-TOF/MS 植物化学谱分析、网络药理学、分子对接、多中心随机对照试验及 MCAO 大鼠模型。
- 大鼠经口灌胃 XZTLF 2.97 或 11.88 g/kg/day 连续 7 天,阳性对照依达拉奉右莰醇 10 mg/kg 腹腔注射。
主要发现
- XZTLF 在化学系统药理学分析中鉴定出 173 种生物活性成分,网络药理学筛选出 NFKB1、BCL2L1、MAPK1、STAT1、CDKN2A、AR、RAF1 和 MMP2 共 8 个核心靶点,并在 IS 患者中通过 ELISA 验证。
- MCAO 大鼠中 XZTLF 给药显著减小脑梗死体积并改善神经功能。
- 机制上 XZTLF 下调 IL-6、TNF-α 和 NF-κB 等促炎介质,调节 MDA、SOD、CAT 以减轻氧化损伤,并抑制 PI3K/AKT 信号通路过度激活。
临床怎么用
- 对急性缺血性卒中患者,XZTLF 可作为潜在中药干预选项,但需结合多中心 RCT 最终结果个体化评估。
局限性
- 研究结论基于临床前及初步临床发现,尚需更充分的高质量临床证据确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke (IS) remains a critical challenge in stroke management. Xiongzhi Tongluo formula (XZTLF), a traditional Chinese herbal prescription, has shown potential in treating ischemic stroke, yet its mechanisms remain elusive. METHODS: This integrated study combined clinical and in vivo approaches to investigate XZTLF. We first employed network node similarity algorithms, ultra-high performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS)-based phytochemical profiling, and network pharmacology to identify potential molecular targets for ischemic stroke (IS) intervention. The predicted hub genes were then validated through molecular docking and a multicenter randomized controlled trial in patients with acute IS. For in vivo validation, a middle cerebral artery occlusion (MCAO) rat model was used. Rats were treated with XZTLF via oral gavage at doses of 2.97 or 11.88 g/kg/day for 7 days, using edaravone dexborneol (10 mg/kg, i.p.) as a positive control. Key targets and mechanisms of action were further assessed through biochemical and histological analyses of rat brain tissue. RESULTS: XZTLF demonstrated significantly closer network-based proximity to IS targets compared to control prescriptions. Chemical systematic pharmacology analysis identified 173 bioactive constituents in XZTLF. Network pharmacology screening revealed eight core targets (NFKB1, BCL2L1, MAPK1, STAT1, CDKN2A, AR, RAF1, and MMP2), which were subsequently validated in IS patients through ELISA quantification. In MCAO rat models, XZTLF administration significantly reduced cerebral infarct volume and improved neurological function. Mechanistically, XZTLF attenuated neuroinflammation by downregulating pro-inflammatory mediators (including IL-6, TNF-α, and NF-κB), mitigated oxidative damage (MDA, SOD, CAT), and suppressed hyperactivation of the PI3K/AKT signaling pathway. CONCLUSION: XZTLF shows potential for treating IS through multimodal regulation of neuroinflammatory cascades, redox homeostasis, and autophagy pathways, based on integrated preclinical and preliminary clinical findings.
引用
- Miao L, Zhao D, Wang L, et al. An integrated approach elucidates Xiongzhi Tongluo formula against ischemic stroke. Phytomedicine. 2026. PMID: 41795297. doi:10.1016/j.phymed.2026.157990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。